Corium International Inc (CORI) was Upgraded by WBB Securities to ” Speculative Buy” and the brokerage firm has set the Price Target at $11. Earlier the firm had a rating of “Hold ” on the company shares. WBB Securities advised their investors in a research report released on May 3, 2016.
Many Wall Street Analysts have commented on Corium International Inc. Shares were Reiterated by Needham on Feb 9, 2016 to “Buy” and Lowered the Price Target to $ 15 from a previous price target of $16 .
Corium International Inc opened for trading at $4.52 and hit $4.8 on the upside on Monday, eventually ending the session at $4.75, with a gain of 6.03% or 0.27 points. The heightened volatility saw the trading volume jump to 27,582 shares. Company has a market cap of $106 M.
In a different news, on Feb 26, 2015, Peter D Staple (CEO) purchased 3,600 shares at $6.99 per share price.
Corium International Inc. is a biopharmaceutical company. The Company is engaged in the development manufacture and commercialization of specialty pharmaceutical products that focuses on transdermal and transmucosal delivery systems. Its development platforms enable transdermal delivery of large molecules or biologics including vaccines peptides and proteins as well as small molecules. Its Corplex and MicroCor platforms address the shortcomings of traditional transdermal drug delivery. Its marketed products include Clonidine TDS which is a treatment for hypertension; Fentanyl TDS which is a treatment for management of chronic pain and Crest Whitestrips are a series of five products for oral care. Its Twirla is designed to deliver both hormones at levels comparable to low-dose oral contraceptives. Its MicroCor hPTH(1?34) is a transdermal system designed to use its MicroCor technology to provide the delivery of parathyroid hormone.